Objective: Hemabate® (15-methyl-prostaglandin F2α) is a relatively new and effective medication for the control of post-partum haemorrhage (PPH). The authors review the literature on the management of PPH, describe their experience with this medication and present the results of a survey of Northern Ontario obstetrical services.Quality of Evidence: numerous studies have demonstrated the effectiveness of Hemabate® for the management of PPH. Despite recommendations regarding its appropriate use in the Advances in Labour and Risk Management (ALARM)1 and Advanced Life Support in Obstetrics (ALSO)2 course guidelines, as well as published reports in the Journal of the Society of Obstetricians and Gynaecologists of Canada (SOGC),3,4 the availability of this medication is somewhat limited in the rural hospitals we surveyed in Northern Ontario.Main Message: Hemabate® is a safe, effective drug for the management of PPH when oxytocin and manual massage and evacuation of the uterus have failed. It is especially useful in rural settings where access to resources may be limited.Conclusion: the authors recommend the more widespread availability and use of Hemabate®, particularly in rural settings.